Urinary Excretion of β-Aminoisobutyrate and Pseudouridine in Acute and Chronic Myeloid Leukemia
End products of nucleic acid metabolism including βaminoisobutyrate (β-AIB) and pseudouridine (ψ-Urd) have been considered as potential biochemical markers for cancer. The urinary excretion of both metabolites was investigated in abnormal hematopoietic conditions including 26 patients with acute mye...
Gespeichert in:
| Veröffentlicht in: | JNCI : Journal of the National Cancer Institute 1983-11, Vol.71 (5), p.887-891 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 891 |
|---|---|
| container_issue | 5 |
| container_start_page | 887 |
| container_title | JNCI : Journal of the National Cancer Institute |
| container_volume | 71 |
| creator | Nielsen, Henrik R. Killmann, Sven-Aage |
| description | End products of nucleic acid metabolism including βaminoisobutyrate (β-AIB) and pseudouridine (ψ-Urd) have been considered as potential biochemical markers for cancer. The urinary excretion of both metabolites was investigated in abnormal hematopoietic conditions including 26 patients with acute myeloid leukemia(AML)and chronic myeloidleukemia(CML) and was compared to that of 25 healthy controls. β-AIB excretion in CML was directly correlated to the leukocyte count, the indicator of tumor cell mass. β-AIB excretion was elevated in 27 and 75% of untreated AML and CML cases, respectively. Marrow blast cell content tended to correlate positively with ψ-Urd excretion in AML. ψUrd excretion was elevated in 82 and 87% of untreated AML and CML, respectively.Turnover of hematopoietic cells seemed to be a determinant for β-AIB excretion, indicating higher cell turnover in CML patients compared to that in AML patients and in controls. With cytostatic treatment, excretion levels of β-AIB and/or ψ-Urd decreased after a transient rise. |
| doi_str_mv | 10.1093/jnci/71.5.887 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_80780576</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>80780576</sourcerecordid><originalsourceid>FETCH-LOGICAL-i273t-e45f20ff02b948054951baa8219570922e9986a153c3738653394a9dec83268e3</originalsourceid><addsrcrecordid>eNo9kMtKLDEQhoN40PGydClkIe56zLWTLMdh1AMjx4WCuGkz3dUY7U406QbntXwQn-kEbCwKCur7KIofoRNK5pQYfvHqa3eh6FzOtVY7aEZFSQpGidxFM0KYKvJa7KODlF5JLsPEHtorpSZC6xl6fojO27jFq886wuCCx6HF31_Fonc-uBQ247CNdgBsfYPvEoxNGKNrnAfsPF7U44SWLzF4V-PbLXTBNXgN4xv0zh6hP63tEhxP8xA9XK3ulzfF-t_13-ViXTim-FCAkC0jbUvYxghNpDCSbqzVjBqp8tMMjNGlpZLXXHFdSs6NsKaBWnNWauCH6Pzn7nsMHyOkoepdqqHrrIcwpkoTlc-qMounkzhuemiq9-j6HEA1RZL52cRtqm3XRpsDTr-aEZLkzlrxo7k0wOcvtvGtKhVXsrp5fKrub-8ELa-uq0v-H1rIfso</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>80780576</pqid></control><display><type>article</type><title>Urinary Excretion of β-Aminoisobutyrate and Pseudouridine in Acute and Chronic Myeloid Leukemia</title><source>MEDLINE</source><source>Oxford University Press Journals Digital Archive Legacy</source><creator>Nielsen, Henrik R. ; Killmann, Sven-Aage</creator><creatorcontrib>Nielsen, Henrik R. ; Killmann, Sven-Aage</creatorcontrib><description>End products of nucleic acid metabolism including βaminoisobutyrate (β-AIB) and pseudouridine (ψ-Urd) have been considered as potential biochemical markers for cancer. The urinary excretion of both metabolites was investigated in abnormal hematopoietic conditions including 26 patients with acute myeloid leukemia(AML)and chronic myeloidleukemia(CML) and was compared to that of 25 healthy controls. β-AIB excretion in CML was directly correlated to the leukocyte count, the indicator of tumor cell mass. β-AIB excretion was elevated in 27 and 75% of untreated AML and CML cases, respectively. Marrow blast cell content tended to correlate positively with ψ-Urd excretion in AML. ψUrd excretion was elevated in 82 and 87% of untreated AML and CML, respectively.Turnover of hematopoietic cells seemed to be a determinant for β-AIB excretion, indicating higher cell turnover in CML patients compared to that in AML patients and in controls. With cytostatic treatment, excretion levels of β-AIB and/or ψ-Urd decreased after a transient rise.</description><identifier>ISSN: 0027-8874</identifier><identifier>EISSN: 1460-2105</identifier><identifier>DOI: 10.1093/jnci/71.5.887</identifier><identifier>PMID: 6580488</identifier><language>eng</language><publisher>Cary, NC: Oxford University Press</publisher><subject>Adult ; Aminoisobutyric Acids - urine ; Biological and medical sciences ; Cytarabine - therapeutic use ; Daunorubicin - therapeutic use ; Female ; Hematologic and hematopoietic diseases ; Humans ; Leukemia, Myeloid - drug therapy ; Leukemia, Myeloid - urine ; Leukemia, Myeloid, Acute - drug therapy ; Leukemia, Myeloid, Acute - urine ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Leukocyte Count ; Male ; Medical sciences ; Middle Aged ; Pseudouridine - urine ; Uridine - analogs & derivatives</subject><ispartof>JNCI : Journal of the National Cancer Institute, 1983-11, Vol.71 (5), p.887-891</ispartof><rights>1984 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=9450450$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/6580488$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nielsen, Henrik R.</creatorcontrib><creatorcontrib>Killmann, Sven-Aage</creatorcontrib><title>Urinary Excretion of β-Aminoisobutyrate and Pseudouridine in Acute and Chronic Myeloid Leukemia</title><title>JNCI : Journal of the National Cancer Institute</title><addtitle>Journal of the National Cancer Institute</addtitle><description>End products of nucleic acid metabolism including βaminoisobutyrate (β-AIB) and pseudouridine (ψ-Urd) have been considered as potential biochemical markers for cancer. The urinary excretion of both metabolites was investigated in abnormal hematopoietic conditions including 26 patients with acute myeloid leukemia(AML)and chronic myeloidleukemia(CML) and was compared to that of 25 healthy controls. β-AIB excretion in CML was directly correlated to the leukocyte count, the indicator of tumor cell mass. β-AIB excretion was elevated in 27 and 75% of untreated AML and CML cases, respectively. Marrow blast cell content tended to correlate positively with ψ-Urd excretion in AML. ψUrd excretion was elevated in 82 and 87% of untreated AML and CML, respectively.Turnover of hematopoietic cells seemed to be a determinant for β-AIB excretion, indicating higher cell turnover in CML patients compared to that in AML patients and in controls. With cytostatic treatment, excretion levels of β-AIB and/or ψ-Urd decreased after a transient rise.</description><subject>Adult</subject><subject>Aminoisobutyric Acids - urine</subject><subject>Biological and medical sciences</subject><subject>Cytarabine - therapeutic use</subject><subject>Daunorubicin - therapeutic use</subject><subject>Female</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Humans</subject><subject>Leukemia, Myeloid - drug therapy</subject><subject>Leukemia, Myeloid - urine</subject><subject>Leukemia, Myeloid, Acute - drug therapy</subject><subject>Leukemia, Myeloid, Acute - urine</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Leukocyte Count</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pseudouridine - urine</subject><subject>Uridine - analogs & derivatives</subject><issn>0027-8874</issn><issn>1460-2105</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1983</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kMtKLDEQhoN40PGydClkIe56zLWTLMdh1AMjx4WCuGkz3dUY7U406QbntXwQn-kEbCwKCur7KIofoRNK5pQYfvHqa3eh6FzOtVY7aEZFSQpGidxFM0KYKvJa7KODlF5JLsPEHtorpSZC6xl6fojO27jFq886wuCCx6HF31_Fonc-uBQ247CNdgBsfYPvEoxNGKNrnAfsPF7U44SWLzF4V-PbLXTBNXgN4xv0zh6hP63tEhxP8xA9XK3ulzfF-t_13-ViXTim-FCAkC0jbUvYxghNpDCSbqzVjBqp8tMMjNGlpZLXXHFdSs6NsKaBWnNWauCH6Pzn7nsMHyOkoepdqqHrrIcwpkoTlc-qMounkzhuemiq9-j6HEA1RZL52cRtqm3XRpsDTr-aEZLkzlrxo7k0wOcvtvGtKhVXsrp5fKrub-8ELa-uq0v-H1rIfso</recordid><startdate>198311</startdate><enddate>198311</enddate><creator>Nielsen, Henrik R.</creator><creator>Killmann, Sven-Aage</creator><general>Oxford University Press</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>198311</creationdate><title>Urinary Excretion of β-Aminoisobutyrate and Pseudouridine in Acute and Chronic Myeloid Leukemia</title><author>Nielsen, Henrik R. ; Killmann, Sven-Aage</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-i273t-e45f20ff02b948054951baa8219570922e9986a153c3738653394a9dec83268e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1983</creationdate><topic>Adult</topic><topic>Aminoisobutyric Acids - urine</topic><topic>Biological and medical sciences</topic><topic>Cytarabine - therapeutic use</topic><topic>Daunorubicin - therapeutic use</topic><topic>Female</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Humans</topic><topic>Leukemia, Myeloid - drug therapy</topic><topic>Leukemia, Myeloid - urine</topic><topic>Leukemia, Myeloid, Acute - drug therapy</topic><topic>Leukemia, Myeloid, Acute - urine</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Leukocyte Count</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pseudouridine - urine</topic><topic>Uridine - analogs & derivatives</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nielsen, Henrik R.</creatorcontrib><creatorcontrib>Killmann, Sven-Aage</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>JNCI : Journal of the National Cancer Institute</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nielsen, Henrik R.</au><au>Killmann, Sven-Aage</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Urinary Excretion of β-Aminoisobutyrate and Pseudouridine in Acute and Chronic Myeloid Leukemia</atitle><jtitle>JNCI : Journal of the National Cancer Institute</jtitle><addtitle>Journal of the National Cancer Institute</addtitle><date>1983-11</date><risdate>1983</risdate><volume>71</volume><issue>5</issue><spage>887</spage><epage>891</epage><pages>887-891</pages><issn>0027-8874</issn><eissn>1460-2105</eissn><abstract>End products of nucleic acid metabolism including βaminoisobutyrate (β-AIB) and pseudouridine (ψ-Urd) have been considered as potential biochemical markers for cancer. The urinary excretion of both metabolites was investigated in abnormal hematopoietic conditions including 26 patients with acute myeloid leukemia(AML)and chronic myeloidleukemia(CML) and was compared to that of 25 healthy controls. β-AIB excretion in CML was directly correlated to the leukocyte count, the indicator of tumor cell mass. β-AIB excretion was elevated in 27 and 75% of untreated AML and CML cases, respectively. Marrow blast cell content tended to correlate positively with ψ-Urd excretion in AML. ψUrd excretion was elevated in 82 and 87% of untreated AML and CML, respectively.Turnover of hematopoietic cells seemed to be a determinant for β-AIB excretion, indicating higher cell turnover in CML patients compared to that in AML patients and in controls. With cytostatic treatment, excretion levels of β-AIB and/or ψ-Urd decreased after a transient rise.</abstract><cop>Cary, NC</cop><pub>Oxford University Press</pub><pmid>6580488</pmid><doi>10.1093/jnci/71.5.887</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0027-8874 |
| ispartof | JNCI : Journal of the National Cancer Institute, 1983-11, Vol.71 (5), p.887-891 |
| issn | 0027-8874 1460-2105 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_80780576 |
| source | MEDLINE; Oxford University Press Journals Digital Archive Legacy |
| subjects | Adult Aminoisobutyric Acids - urine Biological and medical sciences Cytarabine - therapeutic use Daunorubicin - therapeutic use Female Hematologic and hematopoietic diseases Humans Leukemia, Myeloid - drug therapy Leukemia, Myeloid - urine Leukemia, Myeloid, Acute - drug therapy Leukemia, Myeloid, Acute - urine Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Leukocyte Count Male Medical sciences Middle Aged Pseudouridine - urine Uridine - analogs & derivatives |
| title | Urinary Excretion of β-Aminoisobutyrate and Pseudouridine in Acute and Chronic Myeloid Leukemia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T04%3A39%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Urinary%20Excretion%20of%20%CE%B2-Aminoisobutyrate%20and%20Pseudouridine%20in%20Acute%20and%20Chronic%20Myeloid%20Leukemia&rft.jtitle=JNCI%20:%20Journal%20of%20the%20National%20Cancer%20Institute&rft.au=Nielsen,%20Henrik%20R.&rft.date=1983-11&rft.volume=71&rft.issue=5&rft.spage=887&rft.epage=891&rft.pages=887-891&rft.issn=0027-8874&rft.eissn=1460-2105&rft_id=info:doi/10.1093/jnci/71.5.887&rft_dat=%3Cproquest_pubme%3E80780576%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=80780576&rft_id=info:pmid/6580488&rfr_iscdi=true |